ABSTRACT. We evaluated circulating levels of biologically active and immunoreactive intact parathyroid hormone in 47 newborns at birth and eight hypocalcemic preterm infants during the first 10 d of life. Use of two sensitive detection systems, the cytochemical bioassay and an immunoradiometric assay specific for intact parathyroid hormone, enabled us to compare plasma concentrations of PTH-like bioactivity (bioPTH) and iPTH-(1-84). Mean umbilical venous plasma bioPTH was elevated in nondiabetic term and preterm newborns [22.5 + 3.1 (fSEM) and 15.8 f 2.5 ng-equiv/L, respectively] compared with normal adult subjects (9.8 2 2.6 ng-equiv/ L; p < 0.01). Umbilical bioPTH was suppressed in five term infants of diabetic mothers (2.6 f 0.4 ng-equiv/L). In contrast, iPTH-(1-84) was low in term and preterm nondiabetic infants' and term infants of diabetic mothers' umbilical samples (5.4 f 1.5, 4.3 ' . 1.5, and 2.4 + 1.0 ng/ L, respectively). Umbilical venous bioPTH was highly correlated with the magnitude of the transplacental calcium gradient (r = 0.90; p < 0.05). In eight preterm infants studied longitudinally, by 24-36 h of life, declining plasma total and ionized calcium (1.71 f 0.04 and 0.78 f 0.03 mmol/L, respectively) were accompanied by a significant rise in both bioPTH (41.2 f 6.3 ng-equiv/L) and iPTH-(1-84) (56.3 f 11.6 ng/L). These data indicate that the 3rd trimester fetoplacental circulation contains levels of bioPTH several-fold higher than those of immunoreactive intact hormone. We also conclude that even hypocalcemic preterm newborn infants can significantly elevate circulating levels of FTH. (Pediatr Res 29: 201-207,1991) Abbreviations PTH, parathyroid hormone iPTH-(1-84), immunoreactive intact parathyroid hormone bioPTH, parathyroid hormone-like biologic activity IDM, infant of a diabetic mother Can total calcium concentration Ca,, ionized calcium concentration CBA, cytochemical bioassay G6PD, glucose 6-phosphate dehydrogenase DCT, distal convoluted tubule PTHrP, parathyroid hormone-related peptide Received June 14, 1990; accepted October 2, 1990. In humans and other mammals, the extracellular total and ionized calcium concentrations change dynamically during the transition from fetal to extrauterine life. The fetal circulation of mammals in the 3rd trimester is hypercalcemic relative to that of the mother. In humans, cessation of transplacental flow of calcium at birth is associated with decrements in CaT and Ca, concentrations. Blood calcium stabilizes I to 2 d after birth, then rises progressively to levels observed in older children and adults. An exaggeration of this sequence of events, early neonatal hypocalcemia (CaT < 1.75 mmol/L; <7.0 mg/dL), occurs in at least 35 to 50% of preterm newborn infants ( l , 2 ) and more than 90% of extremely preterm infants (3).
In humans and other mammals, the extracellular total and ionized calcium concentrations change dynamically during the transition from fetal to extrauterine life. The fetal circulation of mammals in the 3rd trimester is hypercalcemic relative to that of the mother. In humans, cessation of transplacental flow of calcium at birth is associated with decrements in CaT and Ca, concentrations. Blood calcium stabilizes I to 2 d after birth, then rises progressively to levels observed in older children and adults. An exaggeration of this sequence of events, early neonatal hypocalcemia (CaT < 1.75 mmol/L; <7.0 mg/dL), occurs in at least 35 to 50% of preterm newborn infants ( l , 2 ) and more than 90% of extremely preterm infants (3) .
Inference from other hypercalcemic states has suggested that the chronic hypercalcemia of late fetal existence might suppress fetal PTH secretion (4) and that neonatal parathyroid suppression might persist for several days postpartum, blunting the PTH secretory response to a declining extracellular calcium (4, 5) . A corollary of this hypothesis suggests that the more severe, early neonatal hypocalcemia of preterm babies might result from a transient functional hypoparathyroidism.
Unfortunately, interpretation of levels of immunoreactive PTH measured to date has been hampered both by the immunoheterogeneity of circulating hormone and the preponderance of biologically inactive fragments. Moreover, biologically active PTH circulates in normal subjects at picomolar concentrations (6, 7) , which, until recently, have been beyond the detectability of most assay systems. It is not surprising, then, that iPTH in fetal and umbilical cord blood has been reported as indeterminate or low in some series (5, (8) (9) (10) (11) (12) (13) (14) and normal, or even elevated, compared with maternal or other adult levels (4, (15) (16) (17) (18) in others. A variety of iPTH levels have also been reported in association with early neonatal hypocalcemia (1, 3, 12, 19) .
Using the ultrasensitive CBA for PTH developed by Chambers (20) , Care et al. (21, 22) showed that bioPTH in porcine fetal plasma exceeds paired maternal plasma bioPTH. Similarly, Allgrove et al. (14) reported that human term umbilical cord plasma bioPTH is elevated 5-to 6-fold above paired maternal plasma bioPTH and significantly exceeds values determined in normocalcemic adults. In this report, we have extended these studies by comparing circulating levels of PTH during the perinatal period by means of I) the PTH CBA and 2) a newer, very sensitive immunoradiometric assay specific for intact PTH (Allegro, Nichols Institute Diagnostics, San Juan Capistrano, CA). MA. Of these, 17 were the products of normal term pregnancies, 202 RUBIN 25 were delivered prematurely (26-36 wk gestation), and five were the term offspring of diabetic mothers (White's classification B or greater) (23) . Thirty of the mothers were white, 12 were black, and two Asian. The birth weights of all term and preterm infants and three of the IDM were appropriate for gestational age. The other two IDM were large for gestational age. The immediate causes for preterm birth were preterm labor (n = 2 1) or hypertensive disorders of pregnancy (n = 4). Three sets of preterm twins were studied. Infants of mothers who had received magnesium infusions and infants with either documented or strongly suspected sepsis or perinatal asphyxia or with congenital anomalies were excluded. Gestational age was assessed by the date of last menstrual period, first trimester sonographic evaluation when available, and physical criteria (24) . Physical examinations for all infants studied were performed by the same investigator. Only infants for whom two or more gestational age criteria were concordant (52 wk difference) were included. Last menstrual period and 1 st trimester ultrasound were available for five of the 17 term infants, 10 of the 25 preterm infants (including all multiple gestations), and all five IDM. Otherwise, the specific criteria used for gestational age assessment were physical examination and last menstrual period for nine term and 11 preterm babies, and physical examination and sonogram for the remaining three term and four preterm babies.
MATERIALS AND METHODS
Blood samples were obtained from umbilical vessels immediately after cord clamping and before delivery of the placenta. In a subgroup of eight preterm infants, longitudinal blood samples were also obtained at 24 (n = 4) or 36 h (n = 4) and at 7 to 10 d postpartum via indwelling arterial catheter or by venipuncture. Blood specimens were drawn into cold heparinized tubes as well as into tubes without anticoagulant and then centrifuged at 4°C within 30 min of collection. Aliquots of plasma and serum were stored at -70°C for subsequent analysis. Venous blood samples also were obtained from six normocalcemic adult volunteers (three nonpregnant females, three males) and five parturient women and similarly processed. We have previously reported bioPTH and iPTH-(1-84) values for these five parturient women (25) . Patient recruitment and parental informed consent protocols were approved by the Committee for the Protection of Human Subjects ofthe Brigham and Women's Hospital. Parental consent was obtained for all babies studied.
Assay methods. CBA was performed as reported previously by Chambers et al. (20) and Fenton et al. (26) with minor modifications (27) . The assay procedure is based on the time-and dosedependent stimulation of G6PD activity by PTH in guinea pig renal cortical cells. Vitamin D-supplemented female Hartley strain albino guinea pigs, weighing 450-550 g, were killed and the kidneys removed and decapsulated. Renal cortical segments (approximately 5-7 mm in all dimensions) were preincubated for 5 h at 37°C in nonproliferative synthetic culture medium (Trowell's T8 medium; Grand Island Biological Company, Grand Island, NY) at pH 7.6 in an atmosphere of 95% air and 5% COz. After further incubation in fresh medium for 10 min, each segment was cultured for 6 min with one of the following: I ) graded doses of human PTH-(1-84) reference standard (code 791500, National Institute for Biological Standards and Controls, London, England), 2) dilutions of plasma samples (1:100 or 1: 1000), or 3) dilutions of synthetic purified human PTH-(1-84) in human serum (1: 100 or 1: 1000) (Nichols Institute Diagnostics). All dilutions were performed with Trowell's T8 medium containing 1 % outdated blood bank plasma previously stripped of PTH with QUSO-32 microfine silica (10 mg/mL) (Philadelphia Quartz Co., Valley Forge, PA). Segments were chilled by immersion in hexane on dry ice and stored at -70°C for 1-3 d. Unfixed frozen crystat sections (8 pm) were cut from just below the cortical surfaces at -12°C and then reacted for G6PD activity in 5 mM glucose 6-phosphate, 3 mM NADP, 0.67 mM phenazine methosulfate, 5 mM tetrazolium chloride, 10 mM potassium cyanide, and 20% polyvinyl alcohol in 0.05 M glycyl glycine buffer, pH 8.0. Juxtaglomerular DCT cells were identified by morphologic and, in parallel sections, cytochemical criteria (20) . The intensity of the formazan reaction product within DCT cells was measured by microdensitometry (Zeiss) at 589 nm with an 8-pm mask. The mean absorbancy value for each incubation sample (PTH standard or unknown) was calculated from measurements obtained at 10 to 20 different DCT fields within the same section. Readers were blinded to the identity of the sections.
For immunoabsorption studies, samples were incubated with antibovine PTH guinea pig serum (AS 2 1 114 1, Wellcome Research Laboratories, Beckenham, England) for 30 min at 4°C at a final dilution of 1:5000 before bioassay. This antiserum displays specificity for both human N-terminal (1-34) and C-terminal (53-84) PTH. Cross-reactivity of the antiserum for PTHrP was determined by spiking Quso-stripped human plasma with either synthetic human PTH-(1-34) or PTHrP-(1-34) (Bachem, Torrance, CA) at concentrations of 50 ng/L (approximately 12 pmol/ L) and performing immunoabsorption experiments as described above. Preincubation with this antiserum extinguished 99% of the cytochemical bioactivity of authentic PTH and only 9.5 a 3.8% (n = 5) of the bioactivity of authentic PTHrP.
In several assays, we compared the relative bioactivities of the National Institute for Biological Standards and Controls and Nichols Institute human PTH-(1-84) standards. Both standards were also compared in parallel in the immunoradiometric assay. Our aliquots of National Institute for Biological Standards and Controls PTH possessed 71 + 2% of the activity of equimolar amounts of the Nichols Institute standard. For facility of comparison, all CBA and immunoradiometric PTH data were normalized to a single (Nichols) human PTH-(1-84) standard. CBA results were expressed as ng-equiv/L relative to human PTH-(I-84); 1 ng/L of human PTH-(1-84) is equivalent to 106.1 fmol/ L. The intraassay coefficient of variation for the CBA was 9.0% and the interassay coefficient of variation was 15 % (determined in a normal human plasma pool sample over a 2-y period).
Serum intact PTH was determined in duplicate using the Allegro immunoradiometric assay (Nichols Institute). This technique is a two-site immunoradiometric assay, with two different affinity-purified goat polyclonal antisera to human PTH, one binding the midregion and C-terminal portion of PTH (residues 39-84) and the second binding the N-terminal region of PTH (residues 1-34); the latter is radiolabeled with 1251. The sensitivity of the assay in our laboratory was 1 ng/L (-0.1 pmol/L), and it is believed to quantify accurately the intact form of PTH [PTH-(1-84)] (28). PTH-(1-34) fragments do not cross-react in this assay at concentrations up to 300 ng/L, and PTH fragments 39-68, 53-84, 44-68, and 39-84 do not cross-react at concentrations up to 100 000 ng/L. In our laboratory, the intra-and interassay variations for this system were 2.6 and 5.8%, respectively.
Plasma CaT and Ca, levels were assayed using a NOVA-7 calcium analyzer (NOVA Biomedical, Waltham, MA). Plasma magnesium and phosphorus concentrations were determined in the clinical chemistry laboratory. Magnesium concentrations were determined by atomic absorption spectrometry (interassay coefficient of variation = 5.2%) and phosphorus was determined by standard photometric methods using a DuPont analyzer (interassay coefficient of variation = 2.6%).
Statistical analysis. Descriptive data are expressed as the mean 
term IDM were 22.5 k 3.1, 15.8 * 2.5, and 2.6 + 0.4 ng-equiv/ Plasma CaT, Car, and total magnesium concentrations for the L, respectively. The mean value for Preterm infants was not term and preterm babies and IDM are shown in Table 1 . Total significantly less than that for term babies, whereas that for IDM calcium concentrations for the IDM were significantly lower was significantly less than that for the other groups (P < 0.01). than the CaT for the nondiabetic term infants ( p < 0.005) and Umbilical venous and umbilical arterial bioPTH did not differ for all nondiabetic infants ( p < 0.05).
significantly (36.4 + 9.6 versus 34.9 k 8.6 ng-equiv/L, n = 3).
When paired maternal-neonatal samples that were drawn sihe mean ~~O P T H concentration for six normocalcemic multaneously were compared, umbilical cord bioPTH and calyoung adults studiedconcurrentl~ was 9.8 k 2.6 ng-equiv/L. We cium exceeded the maternal values in each case (Fig. 2) . Thus, recently reported that maternal bioPTH (drawn within 30 min the relatively elevated level of umbilical venous bioPTH in before birth) in five mothers of term infants from this study was normal infants at birth exists in the face of mild umbilical plasma 7.7 2.3 ng-equiv/L (25)> which is to 5'6 + ng-hypercalcemia. When a polyvalent antiserum against PTH was equiv/L normalized to the synthetic human PTH-(1-84) standard described in Materials and Methods. This value is similar to that added to umbilical plasma before CBA, 88 + 3% of bioactivity for nonpregnant adults. For term and preterm infants, mean quenched (n = 3) (Fig. 3) . of plasma from Ito 2-d-old neonates with the same antiserum eliminated essentially all activity in the CBA (97 + 1 %). * (Fig. 2c ).
la
Relationships between bioPTH and intact PTH levels and BioPTH and iPTH-(1-84) also were assayed longitudinally in these preterm babies (Fig. 6 ). Both measures of PTH increased Similarly, in the maternal samples, iPTH-(1-84) was greater than t p < 0.005 vs the nondiabetic term group. bioPTH (12.9 k 1.5 ng/L versus 5.6 k 1 ng-equiv/L, respec-$ p < 0.05 vs the aggregate nondiabetic (term and preterm) group. tively). 
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DISCUSSION
We have shown that levels of bioPTH that exceed those of normal adult subjects are present in human umbilical plasma from at least 26 wk of gestation onward. The mean bioPTH concentration for the six normocalcemic adults is similar to the value obtained previously in a larger group of normal subjects (9.2 + 1.0 ng-equiv/L; n = 51) using a highly purified human PTH-(1-84) standard (Posillico JT, unpublished data). A striking feature of this bioactivity is that it also exceeds umbilical serum immunoreactive, intact PTH by 3-to 4-fold. By comparison, in newborn infants who are several days postpartum, as well as in normal nonpregnant adults and parturient women (25) , iPTH-(1-84) levels are 30-90% greater than bioPTH measured in corresponding samples. Because only minor deletions of the amino-terminus of PTH abolish biologic activity (3 l), it is quite possible that there are circulating forms of the hormone that are immunoreactive in the intact immunoradiometric assay but are not biologically active.
The discordantly elevated bioPTH concentrations measured in umbilical plasma might represent one or more PTH or PTHlike molecular species. Our detection system, the renal CBA, requires ligand binding to PTH-responsive receptors and subsequent stimulation of intracellular G6PD activity (20) . Only PTH-(1-84), N-terminal PTH fragments that contain at least amino acid residues 1-34 (6, 32) , and PTHrP (33) (34) (35) (36) , an etiologic factor in the syndrome of humoral hypercalcemia of malignancy, are known to be stimulatory in this system. PTH-(1-84) is the predominant biologically active form of circulating hormone both under physiologic conditions and in primary hyperparathyroidism (37, 38) . The existence of measurable plasma concentrations of bioactive N-terminal PTH fragments has been controversial. Whereas parathyroid tissue may locally release N-terminal fragments in addition to native hormone (39, 40) , persistence of these forms in the circulation of normal individuals has not been detected. Furthermore, recent evidence suggests that circulating N-terminal metabolites are not generated peripherally in vivo (41) . In contrast, accumulation of N-terminal fragments in plasma may occur during chronic renal failure with secondary hyperparathyroidism. In this disorder, Goltzman and associates reported that gel filtration of human (6) and canine (42) plasma reveals a significant fraction of the total plasma bioPTH coeluting with PTH-(1-34).
Intrauterine PTH metabolism, which might produce unique PTH profiles, has not been studied. Placenta (43) , liver (44) , and kidney are sites of local production of N-terminal metabolites of PTH and, therefore, are potential sources for production of circulating, N-terminal fragments of PTH in utero.
Alternatively, some fraction of umbilical plasma bioPTH might represent circulating forms of PTHrP. Several fetal tissues in different species can synthesize PTHrP, including parathyroid, placental membranes (45, 46) , and liver (47) . Suggestively, human fetuses and patients with humoral hypercalcemia of malignancy do share certain biochemical features, viz. hypercalcemia, elevated bioPTH (48) , and depressed iPTH-(1-84). However, when Goltzman et al. (48) preincubated plasma from patients with humoral hypercalcemia of malignancy with a multivalent antibovine PTH serum and then performed the CBA for PTH, significantly bioactivity remained. This finding contrasts with the results of our preincubation procedure, albeit using a different antibody that does appear to have limited cross-reactivity with N-terminal PTHrP. We observed that this antiPTH antibody effectively quenches most activity of umbilical plasma in the CBA. Although low concentrations of PTHrP might circulate in umbilical plasma, the data do suggest that the predominant umbilical bioactive factors contain epitopes more closely related to PTH. We have not yet measured immunoreactive PTHrP in umbilical plasma. However, a recent report indicates that umbilical plasma has detectable but low levels of PTHrP compared with normal adults (49) .
Our data may suggest a regulatory role for intrauterine bioPTH in maintenance of fetal calcium homeostasis during the third trimester. Low doses of PTH are known to stimulate bone formation in human adults (50, 51) and act as a mitogen for embryonic chondrocytes in vitro (52) . Therefore, the maintenance of slightly elevated bioPTH levels in the fetal circulation, despite ambient hypercalcemia, suggests a potential anabolic role for the fetal skeleton. Conversely, the depressed umbilical bioPTH levels observed in the IDM may contribute to the pathogenesis of the early hypocalcemia frequently associated with these infants. The five IDM studied at birth displayed a trend toward lower plasma magnesium concentrations than either the term or preterm nondiabetic infants. Hypomagnesemia and early neonatal hypocalcemia in IDM have been associated with depressed parathyroid function (53, 54) .
Finally, whether or not the neonatal parathyroid gland can respond to a hypocalcemic stress has been a controversial point (1, 3, 5, 19) . The preterm infants studied here were capable of elevating bioPTH and iPTH-(1-84) several-fold in response to dropping plasma CaT and Ca, concentrations. Indeed, the iPTH-(1-84) levels observed for these 24-to 36-h-old preterm infants are similar to maximal iPTH-(1-84) levels reported for normal adults infused with EDTA (55) . Consequently, simple hypoparathyroidism does not appear to be the principal cause of early neonatal hypocalcemia in preterm infants. 
